Correlation Between SAB Biotherapeutics and MAIA Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and MAIA Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and MAIA Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between SAB Biotherapeutics and MAIA Biotechnology, you can compare the effects of market volatilities on SAB Biotherapeutics and MAIA Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of MAIA Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and MAIA Biotechnology.

Diversification Opportunities for SAB Biotherapeutics and MAIA Biotechnology

-0.24
  Correlation Coefficient

Very good diversification

The 3 months correlation between SAB and MAIA is -0.24. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and MAIA Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on MAIA Biotechnology and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with MAIA Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of MAIA Biotechnology has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and MAIA Biotechnology go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and MAIA Biotechnology

Given the investment horizon of 90 days SAB Biotherapeutics is expected to generate 1.31 times more return on investment than MAIA Biotechnology. However, SAB Biotherapeutics is 1.31 times more volatile than MAIA Biotechnology. It trades about 0.02 of its potential returns per unit of risk. MAIA Biotechnology is currently generating about 0.01 per unit of risk. If you would invest  650.00  in SAB Biotherapeutics on September 24, 2024 and sell it today you would lose (185.00) from holding SAB Biotherapeutics or give up 28.46% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy99.8%
ValuesDaily Returns

SAB Biotherapeutics  vs.  MAIA Biotechnology

 Performance 
       Timeline  
SAB Biotherapeutics 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental drivers, SAB Biotherapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.
MAIA Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days MAIA Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's forward indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

SAB Biotherapeutics and MAIA Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with SAB Biotherapeutics and MAIA Biotechnology

The main advantage of trading using opposite SAB Biotherapeutics and MAIA Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, MAIA Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MAIA Biotechnology will offset losses from the drop in MAIA Biotechnology's long position.
The idea behind SAB Biotherapeutics and MAIA Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Complementary Tools

Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Commodity Directory
Find actively traded commodities issued by global exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments